Novo Nordisk's UBT251 Shows 19.7% Weight Loss in China Phase 2 Trial

Novo Nordisk and its partner, The United Laboratories International Holdings Limited (TUL), announced positive Phase 2 trial results for the experimental obesity drug UBT251. The study was conducted in China, specifically targeting Chinese participants living with overweight or obesity. Clinical data demonstrated a mean weight loss of 19.7% over a 24-week period using a triple agonist approach targeting GLP-1, GIP, and glucagon receptors. Importantly, the drug exhibited a well-tolerated safety profile, consistent with established incretin-based therapies currently on the market. These findings solidify Novo Nordisk's leadership in the competitive global weight-loss sector and highlight the potential of multi-receptor treatments. Analysts suggest the successful trial in the Chinese market serves as a significant catalyst for the company's long-term valuation and innovation strategy.